Browsing Tag
Avidity Biosciences
7 posts
Atrium Therapeutics (Nasdaq: RNA) Q1 results show cash runway and clinical urgency behind precision cardiology bet
Atrium has cash and RNA ambition. The harder test is whether heart-targeted delivery can turn rare cardiomyopathy science into clinical proof.
Can RNA medicines really reach the heart? Atrium Therapeutics (Nasdaq: RNA) is putting $270m on the line
Atrium Therapeutics launches with $270 million to advance RNA medicines for rare genetic cardiomyopathies. Find out why investors are watching closely.
Biggest pharma deals of 2025: How $70bn in M&A reshaped global drug strategy
Find out how Johnson & Johnson, Novartis, and Sanofi led the $70B pharma M&A wave in 2025, reshaping drug development strategy and investor confidence.
Avidity Biosciences (Nasdaq: RNA) opens access to del-zota in DMD44 as BLA filing nears
Avidity Biosciences launches U.S. access program for del-zota in DMD exon 44 patients. See how this ties into FDA submission plans and the Novartis acquisition.
Novartis makes $12bn bet on RNA medicine with Avidity Biosciences acquisition to expand rare-disease pipeline
Find out why Novartis’s $12 billion Avidity Biosciences deal marks a turning point for big pharma’s RNA-therapy ambitions.
Facioscapulohumeral muscular dystrophy market is set to expand through 2034 with gene therapy innovation and FDA acceleration
Facioscapulohumeral muscular dystrophy market to expand across 7MM by 2034, driven by gene therapy, rising diagnosis, and key drug launches from Roche, Avidity, and Epicrispr.
Avidity Biosciences’ del-desiran granted orphan drug designation in Japan for myotonic dystrophy type 1
Find out how Avidity Biosciences' del-desiran could transform treatment for myotonic dystrophy type 1 after securing Japan's first Orphan Drug nod for DM1.